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Identifying patients with asthma-chronic obstructive
pulmonary disease overlap syndrome using latent class analysis
of electronic health record data: a study protocol
Mohammad A Al Sallakh1,2, Sarah E Rodgers1,3, Ronan A Lyons1,3, Aziz Sheikh2,3,4 and Gwyneth A Davies1,2
Asthma and chronic obstructive pulmonary disease (COPD) are two common different clinical diagnoses with overlapping clinical
features. Both conditions have been increasingly studied using electronic health records (EHR). Asthma-COPD overlap syndrome
(ACOS) is an emerging concept where clinical features from both conditions co-exist, and for which, however, there is no consensus
deﬁnition. Nonetheless, we expect EHR data of people with ACOS to be systematically different from those with “asthma only” or
“COPD only”. We aim to develop a latent class model to understand the overlap between asthma and COPD in EHR data. From the
Secure Anonymised Information Linkage (SAIL) databank, we will use routinely collected primary care data recorded in or before
2014 in Wales for people who aged 40 years or more on 1st Jan 2014. Based on this latent class model, we will train a classiﬁcation
algorithm and compare its performance with commonly used objective and self-reported case deﬁnitions for asthma and COPD.
The resulting classiﬁcation algorithm is intended to be used to identify people with ACOS, ‘asthma only’, and ‘COPD only’ in primary
care datasets.
npj Primary Care Respiratory Medicine  (2018) 28:22 ; doi:10.1038/s41533-018-0088-4
BACKGROUND
Asthma and chronic obstructive pulmonary disease (COPD) are
two common different clinical diagnoses with overlapping clinical
features. Global Initiative for Asthma (GINA) deﬁned asthma based
on variable respiratory symptoms and expiratory airﬂow limita-
tion.1 On the other hand, the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) deﬁned COPD based on
persistent respiratory symptoms and airﬂow limitation.2 While
asthma affects people from the early school age, COPD mainly
affects those aged over 40 years with a smoking history. Clinically,
the differentiation between the two diseases and identifying their
overlap in those older people can be challenging.1 Co-existence of
clinical features of both conditions along with persistent airﬂow
limitation has been recently recognised by a joint committee
publication between GOLD and GINA as the asthma–COPD
overlap syndrome (ACOS).3
However, there are currently no universally agreed consensus
clinical deﬁnitions for the diagnosis of asthma,4–9 COPD,10,11 and
ACOS.12–15 Subsequently, the prevalence of these three conditions
is highly dependent on case deﬁnitions and data sources.16–20
In studies conducted using electronic health records (EHR),
identifying patient groups is further complicated by the limitations
of these data, such as missing data and coding errors.21–23 Despite
the lack of consensus clinical deﬁnitions, we expect EHR data of
people with ‘ACOS’ to be systematically different from those with
‘asthma only’ or ‘COPD only’. Case deﬁnitions aiming to
differentiate between those patient groups based solely on
clinical knowledge or face validity may be inaccurate, and
validating them with traditional methods, e.g., review of full
patient records, is time consuming and labour intensive. Cluster-
ing methods overcome these challenges by automatically
identifying subgroups in the population that best explains the
patterns in high-dimensional EHR data, without an a priori
hypothesis about those subgroups and their labels.24 Latent class
analysis (LCA) is such a method that can probabilistically identify
patients with asthma and/or COPD using the available recorded
data.
AIMS
We plan to develop an LCA model to identify and characterise
patients with asthma, COPD and ACOS in Wales. Based on this LCA
model, we will derive a classiﬁcation algorithm and compare its
performance with commonly used objective and self-reported
case deﬁnitions for asthma and COPD.
METHODS
We will use primary care data on asthma and COPD recorded in or before
2014 for a sample of the Welsh population to ﬁnd, using LCA, clinically
meaningful classes (i.e., clusters) related to the two conditions in that year.
We will follow the STROBE25 and RECORD Statements26 in reporting the full
study.
Data sources
We will use the following two deidentiﬁed datasets from the Secure
Anonymised Information Linkage (SAIL) Databank in Wales:27,28
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● The Welsh Demographic Service (WDS) which contains demographic
and administrative information for the National Health Services (NHS)
patients in Wales.
● The General Practitioner (GP) dataset which contains primary care
events, such as diagnoses, clinical ﬁndings, and prescriptions codiﬁed
in Read codes by general practitioners.
At the time of writing of this protocol, the most recent extract of the GP
dataset was in March 2017, covering about 80% of GP surgeries in Wales.
Patient population
The study sample will be randomly selected from the total population of
Wales within the SAIL Databank in 2014. The sampling will be stratiﬁed by
general practices to improve their representativeness. We will determine
the sample size based on the computational capacity in the SAIL Databank
which will be available for this study. The sampling frame will include all
individuals who were aged at least 40 years on 1st January 2014.
Latent class modelling
LCA is a ﬁnite mixture modelling method that aims to divide a sample into
classes or clusters related to a set of observed variables.24,29 LCA assumes
that the patterns in these observed variables can be explained by, in
addition to measurement errors, a hidden categorical variable that divides
the sample into a pre-deﬁned number of distinct classes.
In our study, we will construct observed variables from asthma- and
COPD-related events recorded in the GP Dataset. The construction of
observed variables will be based on their usefulness, from a clinical
perspective, for identifying and distinguishing between patients with
asthma and/or COPD. These variables will include diagnosis, GP visits, and
prescriptions related to asthma and COPD, as well as history of allergy
(including atopic eczema/dermatitis, food allergy, allergic rhinitis, and
anaphylaxis) and smoking history (see Table 1). GP visits and prescriptions
will be queried during 2014, while the other events will be queried in or
any time before 2014.
Model parameters will include proportions of the latent classes and
probabilities of observing the levels of observed variables in each latent
class, a.k.a item–response probabilities. Parameters will be estimated by
the expectation–maximisation (EM) algorithm, which iteratively searches
for maximum–likelihood parameter values for which the data are more
likely to be observed.30 Based on observed characteristics, each individual
is assigned membership probability in each latent class29 and is ﬁnally
assigned to the latent class of maximum membership probability.31
We will begin the modelling for two latent classes and will then
iteratively increase the numbers of latent classes. Model selection will be
based on model diagnostics and interpretability.
We will look for a model for which the Bayesian Information Criterion
(BIC)32,33 is ideally minimum, or becomes ‘stabilised’, indicating no
signiﬁcant improvement in information gain beyond a certain number of
classes. In addition, the selected model should be clinically relevant; we
will use the estimated item–response probabilities to assign labels
consistent with ‘asthma’, ‘COPD’, ‘both’ (ACOS), and ‘none’ to the latent
classes. We will use class shares as prevalence estimates for these clinical
labels among the age groups of 40 and over in 2014.
LCA modelling will be performed using the R package poLCA (version
1.4.1, 2014).34
Derivation of a classiﬁcation algorithm
Based on the LCA model, we will derive a classiﬁcation algorithm to
identify patients with asthma, COPD and ACOS according to their
characteristics. To do so, we will perform recursive partitioning35 using
the assigned latent classes as labels and the aforementioned observed
variables as predictors. We will use the R package rpart (version 4.1–11,
2017)36 for this purpose.
Comparison with other case deﬁnitions
We will compare the LCA model and the derived classiﬁcation algorithm
with other objective and self-reported measures. As objective measures,
we will use deﬁnitions used in the Quality of Outcomes Framework (QOF)
2014–2015 indicators for ‘treated asthma’ (AST001) and ‘COPD’
(COPD001).37 From the Welsh Health Survey (WHS) 2014,38 we will use
self-reported responses on current treatment of ‘asthma’, ‘emphysema’,
and ‘spells of bronchitis that have lasted over 3 years’, with any of the latter
two representing currently-treated COPD. We will treat invalid and missing
responses as negative responses. We will perform the comparisons in the
group of the WHS 2014 participants who were aged 40 years or over on 1st
January 2014, and whose responses where successfully linked to the SAIL
Databank. We will calculate diagnostic accuracy measures of the LCA
model and the classiﬁcation algorithm against each of the above case
deﬁnitions and vice versa.
Ethics, timeline and dissemination
We obtained an approval to use the SAIL Databank from the Information
Governance Review Panel. NHS Research Ethics Committee approval for
this study is not required because we will only use anonymised data. The
data extraction and statistical analysis will be performed between March
and May 2018. The full paper will be submitted for publication in a
respiratory care-related peer-reviewed journal in due course.
DISCUSSION
While the interest in ACOS is growing, there is no consensus
deﬁnition for this emerging and debated concept,39 leading to
wide variations in prevalence and impaired comparability
between studies. With the increasing use of EHR data to study
asthma and COPD, it is important to develop operational
deﬁnitions for ACOS based on such data. In this study, we will
perform LCA on recorded events of diagnosis, prescriptions, and
healthcare utilisation for asthma and COPD in routinely collected
primary care data. By including observed variables for asthma and
Table 1. Observed variables that will be used in the latent class model
Variable Time interval for
calculation
Categories
Asthma related
Asthma diagnosis codes Ever 0, 1+
Age at asthma ﬁrst
diagnosis codes (if any)
– <40, ≥40, no
diagnosis
Asthma GP visits codes Last year 0, 1+
COPD related
COPD diagnosis codes Ever 0, 1+
COPD GP visits codes Last year 0, 1+
COPD-speciﬁc prescriptions
codes*
Last year 0, 1+
Prescriptions
ICS codes Last year 0, 1+
SABA codes Last year 0, 1+
LABA codes Last year 0, 1+
ICS+LABA codes Last year 0, 1+
OCS codes Last year 0, 1+
LTRA codes Last year 0, 1+
Others
Allergy history** Ever No, yes
Smoking history Ever No, yes
Gender – Male, female
Abbreviations: COPD = chronic obstructive pulmonary disease, ICS =
inhaled corticosteroids, GP = general practitioner, LTRA = leukotriene
receptor antagonists, LABA = long-acting β2 agonists, OCS = oral
corticosteroids, SABA = short-acting β2 agonists.
*COPD-speciﬁc prescriptions include: glycopyrronium bromide, indaca-
terol, olodaterol, anticholinergic bronchodilators (ipratropium bromide,
oxitropium bromide, tiotropium, aclidinium, umeclidinium), roﬂumilast,
oxygen cylinders, and COPD rescue packs.
**Allergy includes atopic eczema/dermatitis, food allergy, allergic rhinitis,
and anaphylaxis.
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COPD in the same model, we will be able to identify patients with
either or both conditions (i.e., ACOS).
An inherent limitation of routinely collected EHR data is the lack
of vital pieces of information that are often used to make
diagnoses at the point of care. Unlike diagnosis and prescriptions
which are generally well coded, important diagnostic tests such as
lung function and peripheral eosinophil count are often poorly
and inconsistently recorded in primary care datasets. These
missing data would have been potentially useful for improving
the accuracy of our model. However, it is often difﬁcult to assess
data missingness in event-based databases. The GP Dataset in the
SAIL Databank is a long-format dataset, in which each row
contains a dated code representing a single primary care event.
The presence of a code usually indicates that the corresponding
event occurred. However, when a code is absent, it is often
impossible to ascertain whether the event did not occur or
whether it was simply not recorded or coded. This is a particular
challenge for events that are known to be poorly recorded.
Therefore, since the quality of observed variables is essential in
LCA, we will only include variables that are thought to be of
reasonable quality in the SAIL Databank. In interpreting the
results, we will consider the limitations of EHR-derived data such
as the possibility of missing or incorrect codes and the changes in
coding practices over time.
LCA itself has limitations. The construction of observed
variables, model selection and interpretation involves a level of
subjectivity. The model’s interpretation and usefulness depends
largely on the choice and structure of observed variables. In our
LCA modelling, the clinical meaning of the latent classes will be
based on surrogate variables, such as diagnosis, GP visits, and
prescriptions, rather than on more direct disease markers such as
clinical and laboratory ﬁndings. Nevertheless, we hypothesise that
LCA of these surrogate variables can reasonably distinguish
between patients with asthma, COPD, and ACOS. This will also
provide an opportunity to assess how clustering based on these
surrogate variables will perform compared with that based on
disease markers.40–47 Comparing the LCA model and the
classiﬁcation algorithm against other objective and self-reported
measures will provide useful information about their validity and
performance.
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